Literature DB >> 20599960

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.

Liping Gu1, Hui Chen, Jingsheng Tuo, Xiaowei Gao, Li Chen.   

Abstract

Choroidal neovascularization (CNV) is one of the severe pathological consequences of the end-stage of age-related macular degeneration (AMD). Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in the retinas of AMD patients. Current available agents for the inhibition of VEGF protein such as bevacizumab show significant promise for the treatment of exudative AMD. However, this compound still has limited efficacy and requires multiple administrations; thus, it is associated with a variety of ocular complications, including endophthalmitis and retinal detachment. In this study, we used anti-VEGFA/VEGFR2 or non-specific siRNA and evaluated their suppression of laser-induced choroidal neovascularization (CNV) in mice. Male adult C57BL/6J mice were used in the study. The mice were subjected to laser rupture of Bruch's membrane to induce CNV and then randomized to five groups with six mice per group. The five groups were blank control, vehicle control (5% glucose solution, GS), VEGFA.siRNA, VEGFR2.siRNA, and non-specific siRNA. Two days after laser photocoagulation, each group, with the exception of the blank control group, received 1 microl of the appropriate agent by intravitreal injection to both eyes. Seven days later, after taking fundus photography and fundus fluorescein angiography (FFA), the mice were killed for tissue sampling. Six eyes from three mice in each group were used for choroidal flatmounts to examine CNV. Six eyes from three mice in each group were subjected to RNA extraction for VEGF mRNA quantification by qRT-PCR. Retinal tissue from 2 mice without laser treatment was harvested as the assay reference. The incidence of burns which showed fluorescein leakage was 80.0% in blank control, 75.0% in GS, 55.0% in VEGFA.siRNA, 40.0% in VEGFR2.siRNA and 30.0% in non-specific siRNA group. The flatmounted specimens showed that the retinal pigment epithelium (RPE) was visualized as a uniform hexagonal array in nonlasered areas. On day 7 after laser burn, well-defined isolectin-B4 labeled CNV networks were shown within the burn spots of the 2 control groups. The inhibitory effects of the 3 siRNAs on CNV formation were statistically significant as compared to the 2 control groups. Compared to the control groups, the ocular expression of VEGF mRNA was decreased significantly in the 3 siRNA treated groups. The areas of CNV correlated with the expression of VEGF mRNA. Anti-VEGFA/VEGFR2 or non-specific siRNA can inhibit CNV and attenuate VEGF mRNA expression in a laser-induced mouse model of CNV. We conclude that the siRNAs may be an option for treating patients with exudative AMD, and more studies are needed to test the possible side-effects of the treatment. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599960     DOI: 10.1016/j.exer.2010.06.019

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  16 in total

Review 1.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3.

Authors:  Mark E Kleinman; Hiroki Kaneko; Won Gil Cho; Sami Dridi; Benjamin J Fowler; Alexander D Blandford; Romulo J C Albuquerque; Yoshio Hirano; Hiroko Terasaki; Mineo Kondo; Takashi Fujita; Balamurali K Ambati; Valeria Tarallo; Bradley D Gelfand; Sasha Bogdanovich; Judit Z Baffi; Jayakrishna Ambati
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 3.  A window to innate neuroimmunity: Toll-like receptor-mediated cell responses in the retina.

Authors:  Mark E Kleinman; Jayakrishna Ambati
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  Age-related macular degeneration and the other double helix. The Cogan Lecture.

Authors:  Jayakrishna Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-06       Impact factor: 4.799

5.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

6.  LncRNA CCAT2 promotes angiogenesis in glioma through activation of VEGFA signalling by sponging miR-424.

Authors:  Sheng-Li Sun; Yu-Gao Shu; Mei-Yi Tao
Journal:  Mol Cell Biochem       Date:  2020-04-01       Impact factor: 3.396

7.  The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularization.

Authors:  Wenyan Peng; Ying Yu; Tiejun Li; Yuanyuan Zhu; Hui Chen
Journal:  Mol Vis       Date:  2013-06-11       Impact factor: 2.367

8.  Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells.

Authors:  Aniket Ramshekar; Haibo Wang; Eric Kunz; Christian Pappas; Gregory S Hageman; Brahim Chaqour; David B Sacks; M Elizabeth Hartnett
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

9.  Vitamin k2, a naturally occurring menaquinone, exerts therapeutic effects on both hormone-dependent and hormone-independent prostate cancer cells.

Authors:  Abhilash Samykutty; Aditya V Shetty; Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram; Gouxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Munirathinam Gnanasekar
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-24       Impact factor: 2.629

10.  Increase in peripheral blood mononuclear cell Toll-like receptor 2/3 expression and reactivity to their ligands in a cohort of patients with wet age-related macular degeneration.

Authors:  Yi Zhu; Liang Liang; Dan Qian; Hongsong Yu; Peizeng Yang; Bo Lei; Hui Peng
Journal:  Mol Vis       Date:  2013-08-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.